The neurorehabilitation devices market size is projected to reach US$ 7,086.82 million by 2031 from US$ 2,725.76 million in 2023. The market is expected to register a CAGR of 12.7% during 2023–2031. Technological advancements in neurorehabilitation devices are likely to bring new trends in the neurorehabilitation devices market in the coming years.
The increasing number of survivors of traumatic brain injuries (TBI) who are seeking effective rehabilitation solutions boosts the demand for neurorehabilitation devices, favoring market growth. Additionally, technological advancements in neurorehabilitation, such as robotics and brain-computer interfaces, enhance treatment efficacy and patient engagement, fueling the growth of the neurorehabilitation devices market. The growing occurrence of neurological disorders and an elderly population further contribute to market expansion. Furthermore, a greater understanding of the benefits of early and personalized rehabilitation therapies encourages healthcare providers to adopt innovative neurorehabilitation devices, ultimately enhancing patient outcomes and quality of life.
The neurorehabilitation devices market is rapidly evolving, fueled by advancements in technology and an expanding demand for effective rehabilitation solutions. The rising incidence of strokes and other neurodegenerative disorders among the global population further propels the growth of the market. As per an article titled "Assessing the perception of Parkinson's disease in Al-Ahsa, Saudi Arabia among the visitors of a public campaign: before and after survey," published in April 2024, the prevalence of Parkinson's disease (PD) in Saudi Arabia has been estimated to be 27 per 100,000 population. With aging, the likelihood of developing neurodegenerative conditions increases. This necessitates a robust rehabilitation framework to address the distinctive challenges faced by these individuals, including mobility issues, balance problems, and cognitive decline. Neurorehabilitation devices play a crucial role in improving the quality of life for people suffering from PD. These devices can assist with physical therapy, improve motor skills, and provide cognitive training.
According to an article titled "Stroke care in MENA: challenges, progress, and promising pathways," published in May 2023, in the country, between 8,000 and 10,000 individuals experience a stroke annually. Neurorehabilitation devices are critical for stroke recovery, addressing motor impairments, leveraging innovative technologies, and enhancing patient engagement through immersive therapies. In addition, as healthcare providers increasingly adopt innovative solutions to enhance patient outcomes, the neurorehabilitation devices market is poised for significant growth in the future.
Clinical studies validate the safety and effectiveness of newly developed neurorehabilitation devices. They provide evidence that neurorehabilitation devices help enhance the quality of life of patients with neurological diseases. These studies encourage healthcare centers to integrate these devices into their treatment programs. For instance, "Clinical Study of a Wearable Remote Rehabilitation Training System for Patients with Stroke: Randomized Controlled Pilot Trial" was published in February 2023. The clinical study aimed to design a remote intelligent rehabilitation training system based on wearable devices and human-computer interaction training tasks and evaluate its safety and efficiency.
Researchers at the University of Kansas Medical Center are studying wearable technology as part of a national stroke recovery clinical trial. Experts are testing the effectiveness of wearable devices that stimulate electromagnetic energy in the brain and spinal cord, which may help decrease disability after a stroke.
In December 2022, a clinical trial study, "Effects of robotic rehabilitation using the Erigo device on patients with neurological injury: a systematic review and meta-analysis of randomized clinical trials," was published. The trial studied the effects of the Erigo robotic rehabilitation device on patients with neurological injury based on parameters such as safety, muscle strength, spasticity, functionality, gait/balance, and changes in the level of consciousness. The study concluded that Erigo, as a robotic rehabilitation device, is safe for patients with acquired brain injury and can reduce spasticity in patients with stroke. Thus, the increasing number of clinical studies on neurorehabilitation devices favors the growth of the market worldwide.
Strategic initiatives taken by market players, such as mergers, acquisitions, partnerships, and collaborations, are likely to accelerate innovation, develop expertise, and expand market reach.
In April 2022, Blackrock Neurotech partnered with Phantom Neuro, a neurotech startup, to carry out research and development for Phantom Neuro's patent-pending Phantom X system, which offers patients highly accurate, almost real-time control of current and next-generation assistive devices, such as prosthetics and exoskeletons. This R&D partnership allows Phantom to use Blackrock's decades of experience in neurotechnology and develop biocompatible implantable sensors to bolster the Phantom X platform.
In December 2022, Ekso Bionics—a leader in exoskeleton technology for medical use—announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation. This acquisition will enhance Ekso's product portfolio and improve its strategic relationships with commercial and research partners such as Vanderbilt University. The partnership with Vanderbilt is expected to enhance its research capabilities and product development.
Thus, the strategic initiatives taken by the market players are likely to create lucrative opportunities for the neurorehabilitation market in the near future.
Key segments that contributed to the derivation of the neurorehabilitation devices market analysis are product type, application, and end user.
The geographic scope of the neurorehabilitation devices market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America held a significant share of the market in 2023. The growth of the market is driven by the growing prevalence of neurological disorders, such as cerebral palsy and spinal cord injury, followed by the surging technological advancement in the field of neurorehabilitation devices. In addition, new product launches and increasing research and development for advancing neurorehabilitation devices are projected to accelerate the growth of the neurorehabilitation devices market in the region.
According to the Brain Injury Canada report, TBI is the leading cause of disability, with 2% of Canadians associated with 18,000 hospitalizations annually. According to the Brain Injury Association of Waterloo-Wellington, TBI occurs in 500 out of 100,000 people yearly in Canada; over 6,000 patients become permanently disabled each year due to a TBI. The integration of neurorehabilitation devices is a crucial part of the recovery process for TBI patients. These devices, including robotic systems and cognitive aids, facilitate targeted rehabilitation by providing personalized therapy that enhances motor skills and cognitive functions.
The regional trends and factors influencing the Neurorehabilitation Devices Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Neurorehabilitation Devices Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 2,725.76 Million |
| Market Size by 2031 | US$ 7,086.82 Million |
| Global CAGR (2023 - 2031) | 12.7% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Neurorehabilitation Devices Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Neurorehabilitation Devices Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The neurorehabilitation devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the neurorehabilitation devices market are listed below:
The "Neurorehabilitation Devices Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
North America dominated the neurorehabilitation devices market in 2023.
Blackrock Microsystems Inc, Hocoma AG, Medtronic Plc, Tyromotion GmbH, Ekso Bionics Holdings Inc, BIONIK, Abbott Laboratories, Renishaw Plc, EMOTIV, and BioXtreme Ltd are among the key players operating in the neurorehabilitation devices market.
The increasing prevalence of neurological diseases worldwide and the growing number of clinical studies on neurorehabilitation devices are the most influential factors responsible for the market growth.
The global neurorehabilitation devices market is estimated to register a CAGR of 12.7% during the forecast period.
The estimated value of the neurorehabilitation devices market can reach US$ 7,086.82 million by 2031.